Catalyst Biosciences Profit Margin 2006-2021 | CBIO
Current and historical gross margin, operating margin and net profit margin for Catalyst Biosciences (CBIO) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Catalyst Biosciences net profit margin as of June 30, 2021 is -1399.58%.
|Catalyst Biosciences Annual Profit Margins
|Catalyst Biosciences Quarterly Profit Margins
||Medical - Biomedical and Genetics
Catalyst Biosciences, Inc. is a biopharmaceutical company which focused on creating and developing medicines to address serious medical conditions. The Company's hemostasis product candidates include CB 813d/PF-0520602, CB 2679d/ISU 304 and FXa. Anti-Complement Product consists of CB 2782 and Ophthalmic which are in clinical different trail. Catalyst Biosciences, Inc., formerly known as Targacept, Inc., is based in South San Francisco, Calif.